





Correction: Use of biomaterials for sustained delivery for anti-VEGF to treat retinal diseases

Ivan Seah  · Xinxin Zhao · Qianyu Lin · Zengping Liu · Steven Zheng Zhe Su · Yew Sen Yuen · Walter Hunziker  · Gopal Lingam  · Xian Jun Loh · Xinyi Su

Published online: 22 May 2020
© The Author(s) 2020. This article is published with open access

Correction to: *Eye*
<https://doi.org/10.1038/s41433-020-0770-y>

The original article was published with errors pertaining to the details of the Port Delivery System (PDS) clinical trials.

In paragraph 3 of the section titled “Non-Biodegradable Implants”, several statements require correction. These statements are detailed below along with the corresponding corrections.

1. “The PDS had a mean refill time of 15 months”.
 - In the Phase II LADDER trial, the PDS had a median refill time of 15 months.
2. “The trial is scheduled for completion in May 2022”.
 - The estimated completion date of the Phase III ARCHWAY trial (ClinicalTrials.gov NCT03677934) should be April 2022.
3. “Concurrently, a long-term efficacy and safety trial, the PORTAL trial (ClinicalTrials.gov ID: NCT03683251),

will also evaluate 500 participants for 144 weeks with 24 weeks of periodic refills”.

- Participants in the Phase III PORTAL extension trial will receive refills every 24 weeks for up to 144 weeks.
4. The following statement was made “This trial is scheduled for completion in June 2022.” —The estimated completion date of the Phase III PORTAL trial (ClinicalTrials.gov NCT03683251) should be January 2022.

All of these errors have been corrected in the HTML and PDF versions of this article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.